Erratum

In the Author Index to the 1997 volume of Clinical Cancer Research (Volume 3), which appeared in the December 1997, Part 1 issue (pp. 2519–2526), the names of the authors from articles in the December 1997, Part 2 issue mistakenly have temporary (T) numbers (i.e., T1, T2, etc.) listed next to them instead of page numbers. The names affected, as well as the correct page numbers, are listed below. We apologize for any inconvenience this oversight has caused.

**AUTHOR INDEX**

**December 1997, Part 2**

<table>
<thead>
<tr>
<th>Authors</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adams, J.</td>
<td>2633</td>
</tr>
<tr>
<td>Arber, N.</td>
<td>2696</td>
</tr>
<tr>
<td>Barlogie, B.</td>
<td>2605</td>
</tr>
<tr>
<td>Bast, R. C., Jr.</td>
<td>2708</td>
</tr>
<tr>
<td>Begemann, M.</td>
<td>2696</td>
</tr>
<tr>
<td>Benjamin, R. S.</td>
<td>2648</td>
</tr>
<tr>
<td>Berger, C.</td>
<td>2671</td>
</tr>
<tr>
<td>Blumenschein, G. R.</td>
<td>2633</td>
</tr>
<tr>
<td>Bodey, G. P.</td>
<td>2660</td>
</tr>
<tr>
<td>Braun, D.</td>
<td>2671</td>
</tr>
<tr>
<td>Cabaniillas, F.</td>
<td>2655</td>
</tr>
<tr>
<td>Caderao, J.</td>
<td>2633</td>
</tr>
<tr>
<td>Carbone, P. P.</td>
<td>2614</td>
</tr>
<tr>
<td>Chertov, O.</td>
<td>2682</td>
</tr>
<tr>
<td>Ciaparrone, M.</td>
<td>2696</td>
</tr>
<tr>
<td>de Witt, M.</td>
<td>2671</td>
</tr>
<tr>
<td>DiStefano, A.</td>
<td>2633</td>
</tr>
<tr>
<td>Doki, Y.</td>
<td>2696</td>
</tr>
<tr>
<td>Drinkard, L.</td>
<td>2633</td>
</tr>
<tr>
<td>Einhorn, L. H.</td>
<td>2630</td>
</tr>
<tr>
<td>Erttmann, R.</td>
<td>2671</td>
</tr>
<tr>
<td>Estey, E.</td>
<td>2591</td>
</tr>
<tr>
<td>Fiedler, W.</td>
<td>2671</td>
</tr>
<tr>
<td>Firstenberg, B.</td>
<td>2633</td>
</tr>
<tr>
<td>Fraizer, G. C.</td>
<td>2571</td>
</tr>
<tr>
<td>Frei, E., III</td>
<td>2554</td>
</tr>
<tr>
<td>Freireich, E. J.</td>
<td>2563, 2711, 2723</td>
</tr>
<tr>
<td>Gehan, E. A.</td>
<td>2587</td>
</tr>
<tr>
<td>Grimm, J.</td>
<td>2671</td>
</tr>
<tr>
<td>Gutterman, J. U.</td>
<td>2594, 2723</td>
</tr>
<tr>
<td>Han, E. K.-H.</td>
<td>2696</td>
</tr>
<tr>
<td>Hersh, E. M.</td>
<td>2550, 2551, 2623</td>
</tr>
<tr>
<td>Hester, J.</td>
<td>2666</td>
</tr>
<tr>
<td>Holland, J. F.</td>
<td>2585</td>
</tr>
<tr>
<td>Horstmann, M.</td>
<td>2671</td>
</tr>
<tr>
<td>Hossfeld, K. D.</td>
<td>2671</td>
</tr>
<tr>
<td>Illiger, H.-J.</td>
<td>2671</td>
</tr>
<tr>
<td>Kabisch, H.</td>
<td>2671</td>
</tr>
<tr>
<td>Kantarjian, H. M.</td>
<td>2723</td>
</tr>
<tr>
<td>Keating, M. J.</td>
<td>2598, 2723</td>
</tr>
<tr>
<td>Kröger, N.</td>
<td>2671</td>
</tr>
<tr>
<td>Krüger, W.</td>
<td>2671</td>
</tr>
<tr>
<td>Kurzrock, R.</td>
<td>2581, 2723</td>
</tr>
<tr>
<td>Kuse, R.</td>
<td>2671</td>
</tr>
<tr>
<td>Lau, Y-f. C.</td>
<td>2571</td>
</tr>
<tr>
<td>Livingston, R. B.</td>
<td>2638</td>
</tr>
<tr>
<td>McCredie, K. B.</td>
<td>2723</td>
</tr>
<tr>
<td>McCulloch, E. A.</td>
<td>2676</td>
</tr>
<tr>
<td>Mendelsohn, J.</td>
<td>2703</td>
</tr>
<tr>
<td>Mixson, A. J.</td>
<td>2687</td>
</tr>
<tr>
<td>Murphy, W. J.</td>
<td>2682</td>
</tr>
<tr>
<td>Oppenheim, J. J.</td>
<td>2682</td>
</tr>
<tr>
<td>O’Brien, S.</td>
<td>2723</td>
</tr>
<tr>
<td>Saunders, G. F.</td>
<td>2571</td>
</tr>
<tr>
<td>Schirrmacher, V.</td>
<td>2682</td>
</tr>
<tr>
<td>Schönrock, P.</td>
<td>2671</td>
</tr>
<tr>
<td>Schweichler, L. H.</td>
<td>2633</td>
</tr>
<tr>
<td>Sgambato, A.</td>
<td>2696</td>
</tr>
<tr>
<td>Shimamura, R.</td>
<td>2571</td>
</tr>
<tr>
<td>Stass, S. A.</td>
<td>2687</td>
</tr>
<tr>
<td>Stockschiälder, M.</td>
<td>2671</td>
</tr>
<tr>
<td>Stopeck, A. T.</td>
<td>2623</td>
</tr>
<tr>
<td>Talpaz, M.</td>
<td>2723</td>
</tr>
<tr>
<td>Trapman, J.</td>
<td>2571</td>
</tr>
<tr>
<td>Wang, J. M.</td>
<td>2682</td>
</tr>
<tr>
<td>Weh, H. J.</td>
<td>2671</td>
</tr>
<tr>
<td>Weinstein, I. B.</td>
<td>2696</td>
</tr>
<tr>
<td>Yamamoto, H.</td>
<td>2696</td>
</tr>
<tr>
<td>Zander, A. R.</td>
<td>2671</td>
</tr>
<tr>
<td>Zeller, W.</td>
<td>2671</td>
</tr>
<tr>
<td>Zhou, P.</td>
<td>2696</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

April 1998

Abe, T., 1071
Adachi, Y., 973
Adsay, V., 887
Agarwal, R., 1055
Alimand, M., 993
Al-Kath, A., 887
Alle, K. M., 847
Allman, D., 941
Ansari, R. H., 929
Antelo, M., 829
Aoyama, M., 1039
Atkinson, K., 895
Bailey-Wood, R., 957
Bandealy, M. T., 935
Banken, L., 941
Benedict, W. F., 829
Biggs, J. C., 895
Bone, E. A., 985
Bottone, A. E., 1031
Brockstein, B. E., 929
Brown, K. A., 913
Brown, P. D., 985
Bukowski, R. M., 1039
Cassidy, J., 941
Cherney, B., 1047
Chiari, S., 985
Choi, N., 949
Ciardiello, F., 821
de Beer, E. L., 1031
Dell, J., 835
Dinney, C. P. N., 829
Dirix, L., 941
Einhorn, L. H., 935
El-Naggar, A., 1065
Essig, Y.-P., 879
Faitre, S., 1021
Fan, S., 1047
Ferri, C., 985
Feyes, D. K., 1055
Field, A. S., 847
Fischman, A. J., 949
Fukase, Y., 1013
Funaki, N. O., 855
Furukawa, T., 1071
Ganapathi, M. K., 1039
Garcia, J. C., 929
Garofalo, A., 985
Giaavazzi, R., 985
Glassman, A., 861
Gonin, R., 935
Goodrich, D., 1065
Grossman, H. B., 829
Gu, L., 913
Gurnani, M., 835
Hajian, G., 835
Hamberg, L. M., 949
Harris, L. N., 1005
Henschell, S. M., 847
Hongo, A., 985
Horii, A., 1071
Horsfall, D. J., 963
Hosotani, R., 855
Hu, S.-X., 829
Hunter, G., 835
Imamura, M., 855
Inoue, T., 973
Irby, R., 879
Ishikawa, T., 1013
Isitsuka, H., 1013
Izibeka, E., 1021
Jain, R. K., 949
Jankun, J., 869
Janocko, L. E., 913
Joshi, U., 887
Jun, X., 901
Kamimura, S., 979
Kang, J. J., 879
Kantarian, H. M., 861
Kato, Y., 1071
Kihara, A., 993
Kito, N., 973
Kobayashi, Y., 979
Kodama, J., 979
Kogire, M., 855
Kuan, C.-T., 993
Kudo, T., 979
Lang, A., 1065
Lawrence, R., 1021
Liebert, M., 829
Lim, S. H., 957
Ling, M., 957
Lipari, P., 835
Lippman, M. E., 993
Loehrer, P. J., 935
Lucchini, V., 985
Lucke, J. F., 913
Lupu, R., 1005
Maclsaac, D., 1039
Majumdar, A. P. N., 887
Mani, S., 929
Mao, W., 879
Marshall, V. R., 963
Mayne, K., 963
McCaul, K., 963
McCloud, T., 949
Mendelsohn, J., 819
Meyer, S. C., 929
Mick, R., 929
Miyagi, Y., 979
Mizutani, Y., 979
Mohammad, R. M., 887
Monaco, F., 935
Murray, A., 993
Myers, D. E., 901
Nakamura, K., 979
Narla, R. K., 901
Nicoletti, M. I., 985
Nielsen, L. L., 835
Nishida, M., 1013
Norris, B. J., 895
O’Connor, P. M., 1047
Osterwalder, B., 941
Ouyang, H., 1071
Palmer, J. L., 829
Paredes-Zaghul, A., 879
Pastan, I., 993
Payne, J., 993
Petit, G. R., 887
Pierce, J. H., 993
Pisters, P. W. T., 1065
Pollock, A., 941
Pollock, R. E., 1065
Ramagli, L., 861
Ratain, M. J., 929
Raymond, E., 1021
Raymond, W. A., 963
Reigner, B., 941
Reinhold, W., 1047
Rhinehart, S. N., 929
Ricciardielli, C., 963
Roos, B., 941
Rostovtsev, A., 901
Ruckert, K., 1047
Sarkar, F. H., 887
Sawada, N., 1013
Schilsky, R. L., 929
Seong, D., 861
Shackney, S. E., 913
Shen, Y., 861
Shiraishi, N., 973
Siciliano, M. J., 861
Singh, S. G., 913
Smith, C. A., 913
Smith, G. M., 895
Stadler, W. M., 929
Sun, H., 985
Sutherland, R. L., 847
Suwa, H., 855
Swantkowski, J., 861
Sweeney, L., 913
Swiercz, R., 869
Sykes, P. J., 963
Taber, D., 929
Talpaz, M., 861
Tan, M., 1065
Takas, J., 855
Tang, C., 1005
Tassoletti, G., 985
Thall, P., 861
Tianqi, G., 979
Tortora, G., 821
Twelves, C., 941
Uchino, S., 973
Uckun, F. M., 901
Utoh, M., 941
Vaitkevicius, V. K., 887
Venkatachalam, T., 901
Verweij, J., 941
Voest, E. E., 1031
Vogelzang, N. J., 929
Vokes, E. E., 929
Von Hoffer, D. D., 1021
Waddick, K. G., 901
Wang, L.-M., 993
Weidemann, E., 941
Wen, Y.-J., 957
Wloch, M., 879
Wolfe, J. D., 869
Xu, J., 861
Yakulis, R., 913
Yang, D., 993, 1005
Yang, L., 1005
Yao, J., 1065
Yeatzman, T. J., 879
Yoshikubo, T., 1013
Yoshinouchi, M., 979
Yu, D., 1065
Zaher, A., 869
Zeren, T., 901
Zi, X., 1055
BioClinical Partners, Inc. is a professionally managed Clinical Research Organization focused primarily towards the development of new diagnostic devices.

We are currently seeking oncologists who can help us support a wide range of clinical research protocols.

To review the clinical protocols and learn more about our studies, please contact Robert McKie or our Medical Director, Deborah Heavilin M.D. via tel: (508) 520-0588 or fax: (508) 520-1525.

BIOCLINICAL PARTNERS, INC.
25 Kenwood Circle, Suite 14A, Franklin MA 02038-3201
Tel: USA (508) 520-0588 • Fax: USA (508) 520-1525

National Cancer Institute
Division of Clinical Sciences

Patients Sought for Immunotoxin Studies

The National Cancer Institute (NCI) seeks patients for a new clinical study involving immunotoxin erb-38 — a novel agent in which the variable regions of a monoclonal antibody against HER-2/neu have been linked to a truncated bacterial toxin. The reagent has been bioengineered to recognize the gene product of HER-2/neu.

Patients with breast, stomach, lung, ovarian, or colon cancer whose tumors express HER-2/neu are potential candidates. NCI will provide eligible patients with treatment and travel to the Clinical Center in Bethesda, Maryland. Please call the NCI Clinical Studies Support Center at 1-888-NCI-1937.
Instructions for Authors

Scope
Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy
When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in Clinical Cancer Research, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences' Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator's Institutional Review Board.

Review Process
The review process is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Publication Fees
A page charge of $50 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charge. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Procedures for Submission
Submit papers directly to the Deputy Editor or to one of the seven Senior Editors, each of whom is responsible for a particular area of research. The Deputy Editor and the Senior Editors will conduct the review process with the expert assistance of the journal’s Associate Editors, will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief, Deputy Editor, and Senior Editors can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.

The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Mini Review is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Mini Reviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

Format
Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and numbers that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;

References
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.
SAMPLE REFERENCES:


Figures

Provide four original sets of figures (whether line-cut drawings or half tones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 cm unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity. Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors is $975 per color figure. Submit color figures on flexible backing.

Proofs

Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors’ corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

Typesetting Manuscripts from Computer Disks

Clinical Cancer Research requests the submission of disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author’s responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

Research Areas of the Editor-in-Chief, Deputy Editor, and Senior Editors

John Mendelsohn, M.D., Editor-in-Chief
Department of Educational Publishing Services–227
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6014; Fax: (713) 792-6016
E-mail: jmendelsohn@notes.mdacc.tmc.edu

John Chabner, M.D., Deputy Editor
Department of Thoracic/Head & Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Box 80
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6363; Fax: (713) 796-8655
E-mail: waun_hong@ismq.mda.uth.tmc.edu

Clinical trials targeted at specific malignancies, chemoprevention

Bruce A. Chabner, M.D.
Department of Hematology/Oncology
Massachusetts General Hospital
Cox Building, Room 640
100 Blossom Street
Boston, MA 02114
Phone: (617) 724-3200; Fax: (617) 724-3166
E-mail: chabner.bruc@mhg.harvard.edu

Clinical pharmacology and pharmacokinetics, drug metabolism, drug sensitivity and resistance, drug interactions

Michael B. Kastan, M.D., Ph.D.
Division of Pharmacology and Experimental Therapeutics
Johns Hopkins Hospital, Ross 345
720 Rutland Avenue
Baltimore, MD 21205
Phone: (410) 614-2747; Fax: (410) 614-4095
E-mail: mbkastan@welchlink.welch.jhu.edu

Cell cycle regulation, cell death

Lance A. Liotta, M.D., Ph.D.
Laboratory of Pathology
National Cancer Institute
Building 10, Room 2A33
National Institutes of Health
10 Center Drive, MSC 1500
Bethesda, MD 20892-1500
Phone: (301) 496-3185; Fax: (301) 402-0043
E-mail: lance@helix.nih.gov

Pathology, metastasis

David Sidransky, M.D.
Otolaryngology/Head & Neck Cancer Research
Johns Hopkins University
818 Ross Research Building
720 Rutland Avenue
Baltimore, MD 21205-2196
Phone: (410) 550-5153; Fax: (410) 614-1411
E-mail: dsidrans@welchlink.welch.jhu.edu

Molecular pathogenesis, molecular correlates

Paul Sondel, M.D., Ph.D.
Departments of Pediatrics, Human Oncology, & Genetics
University of Wisconsin Clinical Science Center
K4/448
600 Highland Avenue
Madison, WI 53792
Phone: (608) 263-9069; Fax: (608) 263-4226
E-mail: pmsondel@facstaff.wisc.edu

Immunotherapy and cytokines—preclinical, and clinical trials

Beverly A. Teicher, Ph.D.
Lilly Research Laboratories
Lilly Corporate Center, DC 0540
Indianapolis, IN 46285
Phone: (317) 276-2739; Fax: (317) 277-3652
E-mail: teicher-beverly-a@lilly.com

Experimental therapeutics, preclinical pharmacology, combined modality regimens, animal therapy models

Jeffrey M. Trent, Ph.D.
Laboratory of Cancer Genetics
National Center for Human Genome Research
National Institutes of Health
Building 49, Room 4A22
49 Convent Drive, MSC 4470
Bethesda, MD 20892-4470
Phone: (301) 402-2023; Fax: (301) 402-2040
E-mail: jtrent@nchgr.nih.gov

Genetics, cytogenetics

For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, Department of Educational Publishing Services–227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-6014; Fax: (713) 792-6016
or:
Publications Department, American Association for Cancer Research, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Phone: (215) 440-9300; Fax: (215) 440-9355.
BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 13,500 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
3. an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
4. reduced registration rates at annual meetings;
5. priority notice of small, focused meetings in the AACR’s exciting series of Special Conferences in Cancer Research;
6. substantially reduced registration rates for Special Conferences;
7. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
8. receipt of AACR Newsletters and other important announcements;
9. early notification of and reduced rates for participation in the AACR Employment Register;
10. an up-to-date Membership Directory of over 13,500 member researchers in the cancer field;
11. the professional benefits of the AACR’s public education activities concerning funding for cancer research and press coverage of the latest research findings;
12. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
13. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
14. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application in AACR Office</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be signed, original letter). This letter should describe the candidate’s achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. --OR-- The nominator may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be signed, original letter). --OR-- The seconder may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9412
E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1998 annual dues for active members are $175, $100 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year’s membership dues are paid in full.

Corresponding members are required to pay dues ($100 in 1998) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: ____________________  ____________________  ____________________  DATE OF BIRTH: ____________

LAST  FIRST  M.I.  Month/Day/Year

PRESENT POSITION/TITLE: _____________________________________________________________

INSTITUTIONAL AFFILIATION: _________________________________________________________

INSTITUTIONAL ADDRESS: _____________________________________________________________

(City)  (State/Province)  (Country)  (Postal Code)

TELEPHONE NUMBER: ________________________________  FAX NUMBER: ________________________________

E-MAIL ADDRESS: _________________________________________________________________

PRIMARY FIELD OF RESEARCH (Please check only one):

- Biochemistry and Biophysics
- Biostatistics
- Carcinogenesis
- Cellular Biology and Genetics
- Clinical Investigations
- Endocrinology
- Epidemiology
- Immunology
- Molecular Biology and Genetics
- Preclinical Pharmacology and Virology
- Experimental Therapeutics
- Other: ____________________________________________________________ (Please specify)

ACADEMIC DEGREES (Including where and when granted)

________________________________________________________________________

________________________________________________________________________

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

________________________________________________________________________

________________________________________________________________________

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

________________________________________________________________________

________________________________________________________________________

CANDIDATE IS APPLYING FOR (Check one):  □ ACTIVE  □ CORRESPONDING  MEMBERSHIP

CANDIDATE NOMINATED BY*: ____________________  (Please print)  CANDIDATE SECONDED BY*: ____________________  (Please print)

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

I acknowledge by signing this statement of support that this candidate adheres to accepted ethical scientific standards and has or will make a long-term contribution to cancer research.

________________________________________________________________________

Signature of Nominator*  Date  Signature of Seconder*  Date

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR in good standing.
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration at the annual meeting of the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who coauthors the abstract does not lose his or her own sponsorship privilege);
2. optional subscriptions to the Association’s high-quality journals: Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates; beginning in 1998 associate members will be able to purchase AACR journals for half the price of a regular member subscription;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. the privilege of electing an Associate Member Council that organizes programs benefiting associate members and that presents their concerns to the AACR Board of Directors;
5. the opportunity to stand for election to the Associate Member Council;
6. preferred access to the AACR Employment Register;
7. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
8. substantially reduced registration rates at special conferences;
9. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
10. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
11. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues must accompany the application. Dues for 1998 are $55 for associate members residing in the Americas and $65 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
Fax: 215/440-9412
E-mail: aacr@aacc.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1998 have been set at $55 per year for residents of the Americas and $65 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1998 for the forthcoming annual meeting must have paid dues for 1998. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1998 may retain associate membership until December 31, 2002. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: ___________________________ LAST ___________________________ FIRST ___________________________ M.I. ___________________________ DATE OF BIRTH: ___________________________ Month/Day/Year

INSTITUTIONAL AFFILIATION: ____________________________________________

INSTITUTIONAL ADDRESS: ____________________________________________

(City) ___________________________ (State/Province) ___________________________ (Country) ___________________________ (Postal Code) ___________________________

TELEPHONE NUMBER: ___________________________ FAX NUMBER: ___________________________

E-MAIL ADDRESS: ____________________________________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one):

[ ] Graduate Student [ ] Medical Student

[ ] Physician in Training [ ] Postdoctoral Fellow

Gender: [ ] Male [ ] Female

PRIMARY FIELD OF RESEARCH (Please check only one):

[ ] Biochemistry and Biophysics [ ] Biostatistics

[ ] Cellular Biology and Genetics [ ] Clinical Investigations

[ ] Epidemiology [ ] Immunology

[ ] Experimental Pharmacology and Therapeutics [ ] Virology [ ] Other: ___________________________ (Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

________________________________________________________________________

________________________________________________________________________

__________________________________________

________________________

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

__________________________________________

__________________________________________

CANDIDATE NOMINATED BY*: ___________________________

________________________

(Please print)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: ___________________________ Date: ___________________________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: ___________________________ Date: ___________________________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit one copy of your curriculum vitae. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues. For 1998, dues are $55 for associate members residing in the Americas and $65 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

[ ] current [ ] forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR in good standing.

(This form may be reproduced.)
Guidelines for Submitting Disks
to
American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

- MacWrite
- Microsoft Word (DOS, Windows, and Macintosh)
- WordPerfect (DOS, Windows, and Macintosh)
- XyWrite (DOS and Windows)

Also acceptable:

- Ability
- AmiPro
- A.S-TeX
- Appleworks
- ArborTeX
- ArborText
- ClarisWorks WP
- CPT 8000
- CTOS
- Diablo
- DisplayWrite
- Duet
- Einstein
- Enable
- EXP
- Final Word
- FullWrite
- GemWord Plus
- IBM Writing Assistant
- Interleaf
- LATEX
- Leading Edge
- Lotus Manuscript
- Lotus Write
- Mass 11
- MS Windows Write
- MS Works
- MS Works WP Mac
- Multimate
- Multimate Advantage
- Nisus (to ASCII file)
- NoteWriter
- Obun
- OfficeWriter
- PC Write
- PFS First Choice
- Professional Write
- Q&A Write
- Quark XPress
- Q&A Write
- RagTime MS Works
- Rich Text Format
- RSG (to ASCII file)
- Signature
- SLITEX
- SmartWhere
- SmartWrite II
- SoloWriter
- Sprint
- Stx
- SunWrite
- Symphony
- Text EXecutive
- Textures
- Total Word
- Troff
- µTeX
- Volkswriter
- VuWriter
- Wang OIS
- Wang WPS
- Wang Writer
- Window Works
- Windows Write
- WiziWord
- Wordstar
- Wordstar 2000
- WriteNow
- Xerox

Software packages that we are unable to translate:

- FrameMaker
- PageMaker
- Read, Set, Go
- Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: _______________________________________________________
Name of computer used (e.g., IBM/PS2): _________________________________
Operating system and version (e.g., DOS 3.3): _________________________________
Word processing program and version (e.g., WordPerfect 5.0): _________________________
   [See reverse for acceptable programs.]

Manuscript number: _________________________________
First author: _____________________________________________
Corresponding author (if different from first author): _________________________________
Telephone/FAX numbers: _______________________________________________________

This form (both sides) may be reproduced.
The American Association for Cancer Research Presents

Molecular Biology in Clinical Oncology: A Workshop
Supported by a Generous Grant from the National Cancer Institute

An intensive, one-week summer workshop on molecular biology designed for clinical oncologists in training or in their early academic careers.

July 3-9, 1998
Given Biomedical Institute
Aspen, Colorado

ORGANIZERS

MICHAEL B. KASTAN
The Johns Hopkins
Oncology Center
Baltimore, MD

L. MICHAEL GLODÉ
University of Colorado
School of Medicine
Denver, CO

JENNIFER A. PIETENPOL
Vanderbilt University
School of Medicine
Nashville, TN

- Lectures by leading experts on molecular biology concepts and the latest developments in molecular oncology. Topics include gene therapy, oncogenes and growth factors, tumor suppressor genes, molecular genetics, metastasis genes, and drug design.
- Small group laboratory sessions to demonstrate the important experimental techniques utilized in molecular biology.
- A workshop syllabus containing relevant published papers, references to key articles in the literature, and details on important laboratory procedures.
- Financial support for participants who are physicians in training or oncology fellows.

Faculty

Lectures

KATHLEEN R. CHO/ Baltimore, MD
CHI VAN DANG/ Baltimore, MD
ERIC R. FEARON/ Ann Arbor, MI
TYLER JACKS/ Cambridge, MA
MICHAEL B. KASTAN/ Baltimore, MD
ROBERT S. KERBEL/ Toronto, ON, Canada
MARCE E. LIPPMAI/ Washington, DC

EDISON T. LIU/ Bethesda, MD
A. THOMAS LOOK/ Memphis, TN
SANFORD MARKOWITZ/ Cleveland, OH
HAROLD L. MOSES/ Nashville, TN
GARY J. NABEL/ Ann Arbor, MI
PERRY D. NISEN/ Abbott Park, IL

ELAINE OSTRANDER/ Seattle, WA
DREW PARDOLL/ Baltimore, MD
JENNIFER A. PIETENPOL/ Nashville, TN
FRANK J. RAUSCHER, III/ Philadelphia, PA
NADIA ROSENTHAL/ Charlestown, MA
ERIC J. STANBRIDGE/ Irvine, CA

Laboratory Rotations

MARK S. BOGUSKI/ Bethesda, MD. "Computer Searching in Molecular Biology."
LAB DIRECTOR TO BE ANNOUNCED/ "Specialized Techniques in PCR."
JAMES P. HOEFFLER/ San Diego, CA. "Protein Expression."
ROBERT A. SCLAFAH/ Denver, CO. "Transcript Array Analysis."
LAB DIRECTOR TO BE ANNOUNCED "Inducible Gene Expression Systems."

For further information, contact

American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313
Email: meetings@aacr.org
Methods in Clinical Cancer Research
July 25-31, 1998, Vail Cascade Hotel & Club, Vail, Colorado

Supported by a Major Grant from the National Cancer Institute and Generous Contributions from Amgen, Inc., Bristol-Myers Squibb Oncology, Hoechst Marion Roussel, and Searle, Inc.

- A series of lectures by leaders in the field covering all elements of clinical trials design
- Small group discussion sessions on important techniques in clinical research
- Detailed critique of clinical trial protocols sheet developed by each participant
- Waiver of Registration Fees and Full Travel and Subsistence Support for Oncology Fellows
- Waiver of Registration Fees and Partial Travel and Subsistence Support for Junior Faculty
- Application Deadline: April 30, 1998

PROGRAM COMMITTEE CHAIRPERSONS
Daniel D. Von Hoff and Charles A. Coltman, Jr.

FACULTY

*David S. Alberts, Tucson, AZ
James R. Anderson, Omaha, NE
*Jean Pierre Armand, Paris, France
James M. Boyett, Memphis, TN
Otis W. Brawley, Bethesda, MD
Gregory Burke, Basel, Switzerland
*Gary M. Clark, San Antonio, TX
*Charles A. Coltman, Jr., San Antonio, TX
John J. Crowley, Seattle, WA
Otilia Dalesio, Amsterdam, The Netherlands
Christopher K. Daugherty, Chicago, IL
Ross C. Donehower, Baltimore, MD
Robert T. Dorr, Tucson, AZ
John R. Durant, Alexandria, VA
Janice P. Dutcher, Alexandria, VA
Merrill J. Egorin, Baltimore, MD
Stephen L. George, Durham, NC
Steven Goodman, Baltimore, MD
Margaret Foti, Philadelphia, PA
Susan Hilsenbeck, San Antonio, TX
J. Jack Lee, Houston, TX
John H. Littlefield, San Antonio, TX
*H. Kim Lyerly, Durham, NC
Rosemarie Mick, Philadelphia, PA
Gina P. Petroni, Charlottesville, VA
*Steven Piantadosi, Baltimore, MD
*Paul Sondel, Madison, WI
*Ian F. Tannock, Toronto, Ontario, Canada
*Margaret A. Tempero, Omaha, NE
*Daniel D. Von Hoff, San Antonio, TX
*Cheryl L. Willman, Albuquerque, NM

Additional Faculty to be Announced

*Member of the Workshop Program Committee

SESSION TOPICS

Lectures
- Rational Drug Targets • Pitfalls of Clinical Trials
- Principles of Study Design • Biostatistics for the Clinical Trialist • Preclinical Pharmacology • Phases I, II, and III Trial Design • Principles of Clinical Pharmacology and Pharmacokinetics • Excellent Laboratory Correlates in Early Phase Clinical Trials • Regulatory and Ethical Issues
- Special Considerations for Prevention Trials
- Implications of Molecular Epidemiology Research

Small Group Discussions
- New Measures of Outcome • Cytostatic Agents, Angiogenesis Inhibitors, Growth Factors • Clinical Trials with Biologics
- Research Abstract Presentations that Audiences Remember
- Special Considerations for Surgical Oncology Trials
- The Challenge of Combined Modality Trials
- Special Considerations for Pediatric Oncology Trials
- Special Considerations for Radiation Oncology Trials
- Visiting with the Patient: Presentation of a Clinical Trial

Further Information and Application Forms Available from
American Association for Cancer Research • Public Ledger Building, Suite 826 • 150 S. Independence Mall West
Philadelphia, PA 19106-3483 • Telephone: (215) 440-9300 • FAX: (215) 440-9313 • E-mail: meetings@aacr.org
American Society of Clinical Oncology • 225 Reinekers Lane, Suite 650 • Alexandria, VA 22314
Telephone: (703) 299-1070 • FAX: (703) 299-1044 • E-mail: asco@asco.org